Tag Archive for: ovarian cancer

Oncoinvent achieves 50% recruitment milestone in Phase 2 ovarian cancer study of Radspherin®

/in

Strong recruitment momentum demonstrated in 2026 Year-to-date recruitment has already surpassed total enrollment for 2025 Oslo, Norway, 18 June 2026: Oncoinvent, a clinical-stage radiopharmaceutical company developing Radspherin®, a receptor-independent alpha-emitting therapy to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces that its ongoing Phase 2 trial of […]

Read more

Oncoinvent ASA: Second half 2025 results

/in

Oslo, Norway, 26 February 2026: Oncoinvent (OSE: ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces its second half 2025 results. Read more…

Read more

Oncoinvent to Present Positive 24-month Follow-up Data from Phase 1 Ovarian Cancer Study of Radspherin® at ESGO 2026

/in

9 of 10 patients at the highest dose remained free from peritoneal recurrence at 24 months at the recommended dose Oslo, Norway, 17 February 2026 – Oncoinvent, a biotech developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announced that it will present […]

Read more

Four additional sites open for recruitment in Oncoinvent’s Phase 2 trial

/in

Oslo, Norway, 29 January 2026: Oncoinvent, a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers, today announces that the first patient has been enrolled at one of the newly activated sites in its Phase 2 study of Radspherin® in patients with peritoneal carcinomatosis from ovarian cancer. Read more…

Read more
© Optimum Strategic Communications.